Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_assertion type Assertion NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_head.
- NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_assertion description "[Since Cot represents an alternative mode, independently of RAF, to activate Erk1/2, all these data strongly suggest that molecular targeting of Cot may be a potential new specific strategy for ALCL lymphomas therapy, without the fully disturbance of the Erk1/2 function.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_provenance.
- NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_assertion evidence source_evidence_literature NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_provenance.
- NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_assertion SIO_000772 21741362 NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_provenance.
- NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_assertion wasDerivedFrom befree-20150227 NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_provenance.
- NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_assertion wasGeneratedBy ECO_0000203 NP644948.RAU0coqw5xBNQ1wSX38CFXpAndmWiAEknJ3InaNtDuN2U130_provenance.